BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26673822)

  • 1. A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma.
    Hu Z; Wang X; Fang H; Liu Y; Chen D; Zhang Q; Liu X; Wei D; Qu C; Wang S
    Oncotarget; 2016 Feb; 7(5):5664-76. PubMed ID: 26673822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer.
    Gu J; Han T; Ma RH; Zhu YL; Jia YN; Du JJ; Chen Y; Jiang XJ; Xie XD; Guo X
    Int J Oncol; 2014 Feb; 44(2):481-90. PubMed ID: 24297342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells.
    Sun X; Zhang J; Wang Z; Ji W; Tian R; Zhang F; Niu R
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma.
    Hu Z; Fang H; Wang X; Chen D; Chen Z; Wang S
    Oncol Rep; 2014 Jul; 32(1):205-12. PubMed ID: 24858400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excitatory neuron-specific SHP2-ERK signaling network regulates synaptic plasticity and memory.
    Ryu HH; Kim T; Kim JW; Kang M; Park P; Kim YG; Kim H; Ha J; Choi JE; Lee J; Lim CS; Kim CH; Kim SJ; Silva AJ; Kaang BK; Lee YS
    Sci Signal; 2019 Mar; 12(571):. PubMed ID: 30837304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the effect of D61G mutation on SHP2 cause gain of function activity by a molecular dynamics study.
    Li HL; Ma Y; Zheng CJ; Jin WY; Liu WS; Wang RL
    J Biomol Struct Dyn; 2018 Nov; 36(14):3856-3868. PubMed ID: 29125030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development.
    Deng R; Zhao X; Qu Y; Chen C; Zhu C; Zhang H; Yuan H; Jin H; Liu X; Wang Y; Chen Q; Huang J; Yu J
    Oncotarget; 2015 Apr; 6(11):9355-69. PubMed ID: 25823821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.
    De Rocca Serra-Nédélec A; Edouard T; Tréguer K; Tajan M; Araki T; Dance M; Mus M; Montagner A; Tauber M; Salles JP; Valet P; Neel BG; Raynal P; Yart A
    Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4257-62. PubMed ID: 22371576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SHP2E76K mutant promotes lung tumorigenesis in transgenic mice.
    Schneeberger VE; Luetteke N; Ren Y; Berns H; Chen L; Foroutan P; Martinez GV; Haura EB; Chen J; Coppola D; Wu J
    Carcinogenesis; 2014 Aug; 35(8):1717-25. PubMed ID: 24480804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
    Fragale A; Tartaglia M; Wu J; Gelb BD
    Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability
    Yuan Y; Fan Y; Gao Z; Sun X; Zhang H; Wang Z; Cui Y; Song W; Wang Z; Zhang F; Niu R
    Cancer Biol Med; 2020 Aug; 17(3):707-725. PubMed ID: 32944401
    [No Abstract]   [Full Text] [Related]  

  • 13. Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth.
    Bertotti A; Comoglio PM; Trusolino L
    J Cell Biol; 2006 Dec; 175(6):993-1003. PubMed ID: 17158954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
    Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
    Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/β-catenin signaling pathway.
    Zhang Q; Li Y; Zhao R; Wang X; Fan C; Xu Y; Liu Y; Li J; Wang S
    Mol Carcinog; 2018 May; 57(5):619-628. PubMed ID: 29323748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gab1, SHP2, and protein kinase A are crucial for the activation of the endothelial NO synthase by fluid shear stress.
    Dixit M; Loot AE; Mohamed A; Fisslthaler B; Boulanger CM; Ceacareanu B; Hassid A; Busse R; Fleming I
    Circ Res; 2005 Dec; 97(12):1236-44. PubMed ID: 16284184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.
    Edwards MA; Crombie K; Schramm C; Krenz M
    J Appl Physiol (1985); 2015 Jan; 118(1):124-31. PubMed ID: 25359717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment.
    Quintana E; Schulze CJ; Myers DR; Choy TJ; Mordec K; Wildes D; Shifrin NT; Belwafa A; Koltun ES; Gill AL; Singh M; Kelsey S; Goldsmith MA; Nichols R; Smith JAM
    Cancer Res; 2020 Jul; 80(13):2889-2902. PubMed ID: 32350067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
    Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
    ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functions of Shp2 in cancer.
    Zhang J; Zhang F; Niu R
    J Cell Mol Med; 2015 Sep; 19(9):2075-83. PubMed ID: 26088100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.